Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
Authors:
- Ana Fernández MontesAMAna Fernández Montes
- Alberto Carmona-BayonasACAlberto Carmona-Bayonas
- Paula Jimenez-FonsecaPJPaula Jimenez-Fonseca
- Francisca Vázquez RiveraFRFrancisca Vázquez Rivera
- Nieves Martinez LagoNLNieves Martinez Lago
- Marta Covela RúaMRMarta Covela Rúa
- Antía Cousillas CastiñeirasACAntía Cousillas Castiñeiras
- Paula Gonzalez VillarroelPVPaula Gonzalez Villarroel
Open Access
- 12 July 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Abstract
Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor burden and indolent disease. Other models in refractory mCRC are the FAS-CORRECT and Colon Life nomogram. The main objective was to externally validate the prognostic factors of the RECOURSE and FAS-CORRECT trials, and the Colon Life nomogram in a multicenter, real-world series of mCRC treated in 3rd and successive lines with trifluridine/tipiracil. The secondary aim was to develop an OS predictive model, TAS-RECOSMO. Between 2016 and 2019, 244 patients were recruited. Median OS was 8.15 vs 8.12 months for the poor (85% of the subjects) and good (15%) prognosis groups from the RESOURCE trial, respectively, log-rank p = 0.9. The most common grade 3–4 toxicities were neutropenia (17%), asthenia (6%), and anemia (5%). The AFT lognormal model TAS-RECOSMO included six variables: ECOG-PS, KRAS/NRAS/BRAF mutation status, time between diagnosis of metastasis and beginning of trifluridine/tipiracil, NLR, CEA, and alkaline phosphatase. The model’s bootstrapped bias-corrected c-index was 0.682 (95% CI, 0.636–0.722). The factors from the Colon Life model, FAS-CORRECT, and RECOURSE displayed a c-index of 0.690, 0.630, and 0.507, respectively. TAS-RECOSMO, FAS-CORRECT, and the Colon Life nomogram appear to predict OS in patients with refractory mCCR who begin trifluridine/tipiracil treatment in the real world. The prognostic groups of the RECOURCE RCT were unable to capture the situation of real-world subjects treated with trifluridine/tipiracil in this series.Keywords
This publication has 26 references indexed in Scilit:
- Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumabBritish Journal of Cancer, 2017
- Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogramAnnals of Oncology, 2016
- Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programBMC Cancer, 2016
- Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programBMC Cancer, 2016
- Chemotherapy Use, Performance Status, and Quality of Life at the End of LifeJAMA Oncology, 2015
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2015
- Regression Modeling Strategies2015
- External validity: the neglected dimension in evidence rankingJournal of Evaluation in Clinical Practice, 2006
- The cost of dichotomising continuous variablesBMJ, 2006
- Exclusion Criteria Used in Antidepressant Efficacy TrialsJournal of Nervous & Mental Disease, 2004